Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
Stephens & Co. Reiterates Equal-Weight on Amedisys, Maintains $103 Price Target
Stephens & Co. analyst Scott Fidel reiterates Amedisys (NASDAQ:AMED) with a Equal-Weight and maintains $103 price target.
What 10 Analyst Ratings Have To Say About Amedisys
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Barclays Initiates Coverage On Amedisys with Equal-Weight Rating, Announces Price Target of $93
Barclays analyst Steve Valiquette initiates coverage on Amedisys (NASDAQ:AMED) with a Equal-Weight rating and announces Price Target of $93.
RBC Capital Maintains Outperform on Amedisys, Lowers Price Target to $111
RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $114 to $111.
Benchmark Reiterates Buy on Amedisys, Maintains $120 Price Target
Benchmark analyst Bill Sutherland reiterates Amedisys (NASDAQ:AMED) with a Buy and maintains $120 price target.
Benchmark Maintains Buy on Amedisys, Lowers Price Target to $120
Benchmark analyst Bill Sutherland maintains Amedisys (NASDAQ:AMED) with a Buy and lowers the price target from $135 to $120.
Credit Suisse Maintains Outperform on Amedisys, Lowers Price Target to $115
Credit Suisse analyst Jonathan Yong maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $140 to $115.
Analyst Ratings for Amedisys
Amedisys (NASDAQ:AMED) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Oppenheimer Maintains Outperform on Amedisys, Lowers Price Target to $125
Oppenheimer analyst Colin Rusch maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $145 to $125.